Alder fleshes out timeline for migraine candidate

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) gained $7.04 (23%) to $37.23 on Friday after spelling out milestones expected next half for migraine candidate ALD403 during its 1Q15 earnings call.

Alder plans to begin a pivotal trial in 2H15 of an IV formulation of ALD403, administered quarterly, to treat patients with chronic and frequent episodic migraines; it expects top-line data in 1H17. The company remains on track to report preliminary data next half from a Phase IIb dose-ranging trial of the mAb targeting calcitonin gene-related peptide ( CGRP) to prevent chronic migraines. ...